CASE PRESENTATION {#s1}
=================

With a global prevalence of ∼3% and cases projected to reach 53--65.5 million by 2020, primary open-angle glaucoma (POAG) is the leading cause of irreversible blindness worldwide ([@MCS004374CRIC22]; [@MCS004374CRIC26]; [@MCS004374CRIC8]; [@MCS004374CRIC27]).

Most cases of POAG are multifactorial in etiology. However, monogenic autosomal dominant inheritance patterns may account for up to 10% of glaucoma cases, including certain presentations of POAG ([@MCS004374CRIC11]). Of particular note, juvenile-onset high-tension POAG with intraocular pressure (IOP) typically ≥40 mmHg (normal \< 20 mmHg) has been associated with mutations in the myocilin gene *MYOC* (NM_000261), which may also account for up to 5% of adult-onset disease ([@MCS004374CRIC21]; [@MCS004374CRIC2]; [@MCS004374CRIC25]).

Our proband ([Fig. 1](#MCS004374CRIF1){ref-type="fig"}A, patient IV-2) is a 24-yr-old female who was diagnosed with bilateral POAG at age 9 yr. Her condition was medically managed until age 18 yr when IOP rose to 42 mmHg. Increased disc cupping was also noted at this time.

![(*A*) The IV-2 family pedigree. The proband, IV-2, has a four-generation family history of early-onset glaucoma, including her great-grandfather (I-1), her grandmother (II-1), her father (III-1), and her siblings (IV-1 and IV-3). All living relatives with POAG are heterozygous for the p.Glu385Lys *MYOC* mutation, whereas unaffected relatives are homozygous wild-type. IV-2 does not have a family history of breast cancer or any known genetic risk factors for breast cancer. (*B*) Sanger sequencing. The c.1153G\>A, p.Glu385Lys variant found in the proband and affected family members with POAG is demonstrated in comparison to the G/G reference sequence. (*C*) Conservation and location of the c.1153G\>A, p.Glu385Lys variant. The p.Glu385Lys variant, which exchanges a highly conserved negatively charged glutamic acid for a positively charged lysine residue, occurs in the olfactomedin exon 3 of *MYOC,* the same region as a majority of previously identified POAG-associated *MYOC* mutations.](MCS004374Cri_F1){#MCS004374CRIF1}

She underwent trabeculectomy procedures at age 18 (oculus sinister) and 20 (oculus dexter) yr. Both procedures were complicated by hypotony maculopathy requiring two revisions. Since then, her glaucoma has been managed without medications. Upon exam at age 24 yr, she had 20/25 vision in both eyes, corrected with glasses. Her IOP is currently stable at ∼9--13 mmHg in both eyes.

The proband is one of three siblings born to nonconsanguineous Hispanic parents. Her brother was diagnosed with bilateral juvenile-onset POAG at age 19 yr and her sister received the same diagnosis at age 20 yr (patients IV-1 and IV-3). Her brother\'s condition is currently managed with medical therapy, but her sister has undergone a trabeculectomy. Her father (patient III-1) was diagnosed with juvenile-onset POAG in his 20s and received a trabeculectomy at age 26 following initial medical management. He also has adult-onset diabetes mellitus, but is otherwise healthy. Her mother (patient III-2) has adult-onset glaucoma.

The proband\'s paternal grandmother (patient II-1) had early-onset glaucoma and adult-onset diabetes. She began medical therapy in her 30s and later underwent trabeculectomy and laser surgery procedures. Her paternal great-grandfather (patient I-1) also had early-onset glaucoma, which led to significant visual impairment by his mid-30s and eventually rendered him blind.

TECHNICAL ANALYSES {#s2}
==================

The proband was referred for genetic testing following a diagnosis of stage IIa ductal adenocarcinoma of the breast at age 23 yr. Prior to exome sequencing, a commercially available panel evaluating genes associated with hereditary cancer was sent and found to be negative.

Subsequent germline exome sequencing of the proband and her parents, which was completed under a research protocol at the Yale Center for Genome Analysis ([Table 1](#MCS004374CRITB1){ref-type="table"}), also failed to identify any known genetic risk factors for breast cancer. However, given that the proband and her father both have juvenile/early-onset POAG, we examined their sequences for rare heterozygous variants in common that were also not present in her mother\'s sequence ([Table 2](#MCS004374CRITB2){ref-type="table"}). Among these, we identified a novel variant in *MYOC*, NM_000261.2:c.1153G\>A, p.Glu385Lys, located at a highly conserved residue within the olfactomedin-homology domain in exon 3 ([Table 3](#MCS004374CRITB3){ref-type="table"}). Multiple in silico algorithms, including CADD, SIFT and PolyPhen, predict this to be a deleterious variant. Furthermore, this variant is extremely rare, given that it is absent from the gnomAD database.

###### 

Sequencing metrics

                               Proband   Father   Mother
  --------------------------- --------- -------- --------
  Read length                    99        99       99
  Num reads (M)                 45.8      49.3     57.9
  Num bases (G)                  4.5      4.9      5.7
  Mean coverage                 41.6      43.8     50.7
  Median coverage                39        40       48
  PCR duplicates               20.38%    22.49%   24.71%
  Multiply mapped               6.25%    6.57%    6.36%
  Unmapped                      0.05%    0.06%    0.04%
  Reads on-target              53.63%    51.56%   51.55%
  Bases on-target              42.65%    41.05%   41.12%
  Mean error rate               0.24%    0.26%    0.22%
  1× target base coverage       95.1%    95.1%    95.1%
  2× target base coverage       94.9%    94.9%    94.9%
  4× target base coverage       94.7%    94.7%    94.7%
  8× target base coverage       94.1%    94.1%    94.3%
  10× target base coverage      93.5%    93.6%    94.1%
  15× target base coverage      90.4%    90.8%    92.7%
  20× target base coverage      84.7%    85.4%    89.8%
  30× target base coverage      67.9%    69.6%    78.8%
  40× target base coverage      48.7%    51.5%    63.5%
  50× target base coverage      31.7%    35.3%    47.3%
  100× target base coverage     1.8%      2.7%     4.5%

###### 

Rare heterozygous variants

  Gene         Chromosome        HGVS cDNA                                 HGVS protein   Max freq         CADD       SIFT    PPH
  ------------ ----------------- ----------------------------------------- -------------- ---------------- ---------- ------- -------
  *WDR63*      1:85589887        NM_145172:c.2065C\>G                      p.L689V        0                24.9       D       D
  *GOLPH3L*    1:150667289       NM_018178:c.26G\>A                        p.R9H          1.66 × 10^−05^   27.2       D       D
  ***MYOC***   **1:171605427**   **NM_000261.2:c.1153G\>A**                **p.E385K**    **0**            **26.2**   **D**   **D**
  *RC3H1*      1:173915647       NM_172071:c.2928G\>T                      p.Q976H        0                26.5       D       D
  *PRKD3*      2:37486821        NM_005813:c.2050C\>T                      p.L684F        0                29.6       D       D
  *LRP1B*      2:141660657       NM_018557:c.3598C\>A                      p.P1200T       0                25.5       D       D
  *NCKIPSD*    3:48716342        NM_016453:c.1760C\>T                      p.S587F        0                28.3       D       D
  *NIPAL1*     4:48032145        NM_207330:c.322G\>A                       p.G108R        0                34         D       D
  *CSF1R*      5:149433678       NM_005211:c.2873A\>T                      p.D958V        8.81 × 10^−05^   25.6       D       D
  *RPS6KA2*    6:167275598       NM_001006932:c.61G\>C                     p.E21Q         0                22.4       T       D
  *FREM1*      9:14845969        NM_144966:c.1382T\>G                      p.L461R        0                26.6       D       D
  *GCNT1*      9:79118564        NM_001490:c.1267T\>A                      p.L423M        0                22.9       D       P
  *FANCF*      11:22646752       NM_022725:c.604delC                       p.L202X        0                .          .       .
  *MUC15*      11:26587076       NM_001135092:c.410dupC                    p.P137fs       0                .          .       .
  *SLC3A2*     11:62648607       NM_002394:c.415G\>C                       p.E139Q        1.27 × 10^−05^   25.9       T       D
  *SLC22A24*   11:62849139       NM_001136506:c.1286-1G\>A (splice site)                  0                22.9       .       .
  *USPL1*      13:31232910       NM_005800:c.2696A\>G                      p.E899G        0                23.6       D       B
  *FARP1*      13:99083345       NM_005766:c.1954G\>A                      p.E652K        0                29.2       D       P
  *MLYCD*      16:83932751       NM_012213:c.2T\>C                         p.M1T          0                23.3       D       B
  *CHMP1A*     16:89713647       NM_001083314:c.325C\>T                    p.R109X        3.46 × 10^−05^   .          .       .
  *ATG4D*      19:10662583       NM_032885:c.977G\>A                       p.R326H        0                25         D       D
  *MYO9B*      19:17263484       NM_004145:c.966G\>T                       p.K322N        0                27.6       D       P
  *KMT2B*      19:36213545       NM_014727:c.2647C\>T                      p.R883W        9.01 × 10^−06^   34         D       D
  *RASGRP4*    19:38903346       NM_170604:c.1646G\>A                      p.R549Q        9.00 × 10^−06^   25.8       T       D
  *ACTR5*      20:37400367       NM_024855:c.1732C\>G                      p.R578G        0                23.7       D       B
  *FAM65C*     20:49214136       NM_080829:c.1759G\>C                      p.G587R        0                25.5       D       D
  *ZMAT5*      22:30127219       NM_019103:c.508G\>A                       p.G170S        3.53×10^−05^     34         D       D

Following full exome sequencing, multiple rare heterozygous variations were identified in common between the proband and her father, with her mother\'s exome as a reference. This table details all shared variants (heterozygous in the proband and her father, a reference in proband\'s mother) with a population frequency of \<0.1%. The *MYOC* variant is in bold.

(Max freq) the maximum frequency of a variant in any population in the public gnomAD database, (0) the particular variant has not be reported in gnomAD, (CADD, SIFT, PPH) in silico predictors of the likelihood that a variant is deleterious, (T) tolerated, (D) deleterious, (B) benign, (P) pathogenic.

###### 

Details of *MYOC* gene variant

  Gene     Chr   HGVS DNA (GRCh37)   HGVS cDNA                HGVS protein   Variant type   Predicted effect   dbSNP ID       Genotype       ClinVar ID
  -------- ----- ------------------- ------------------------ -------------- -------------- ------------------ -------------- -------------- --------------
  *MYOC*   1     g.171605427C\>T     NM_000261.2 c.1153G\>A   p.Glu385Lys    Substitution   Deleterious        rs1033533679   Heterozygous   SCV000897705

Subsequently, we sequenced this locus in the proband and all available first- or second-degree family members using Sanger sequencing. All individuals with juvenile/early-onset POAG---the proband, her father, and her two siblings---were determined to be heterozygous for this missense variant ([Fig. 1](#MCS004374CRIF1){ref-type="fig"}B). In contrast, all unaffected individuals---the proband\'s mother, maternal grandmother, and paternal grandfather---did not have this variant in *MYOC*. These results indicate that this variant segregates with the disease phenotype in this family.

Following ACMG guidelines for interpretation, we classified the *MYOC* p.Glu385Lys variant as Likely Pathogenic, based on two moderate and two supporting criteria: PM2 (absent from controls in gnomAD) and PP1_Moderate (cosegregation with disease with multiple family members); and PP3 (multiple lines of computational evidence) and PP4 (specificity of *MYOC* causing heritable early-onset POAG with elevated IOP, as opposed to other known genetic causes, *OPTN* and *TBK1*, that cause early-onset normal tension glaucoma with IOP ≤ 21 mmHg) ([@MCS004374CRIC17]; [@MCS004374CRIC9]; [@MCS004374CRIC18]; [@MCS004374CRIC25]).

DISCUSSION {#s3}
==========

*MYOC* is a three-exon gene located on Chromosome 1q23-24 that codes for myocilin. It is highly expressed in several eye structures---in particular, the trabecular meshwork (TM), which is known to play a role in regulating IOP ([@MCS004374CRIC12]; [@MCS004374CRIC15]; [@MCS004374CRIC5]; [@MCS004374CRIC11]; [@MCS004374CRIC24]). Myocilin contains several functional domains, including a carboxy-terminal peroxisomal targeting domain and an olfactomedin domain---a region homologous to a family of secreted glycoproteins with uncertain function ([@MCS004374CRIC4]; [@MCS004374CRIC11]).

Although the association of *MYOC* with POAG is well-established, the normal function of the myocilin protein remains unclear. In fact, the lack of a discernible ocular phenotype in mice homozygous for a targeted null *Myoc* mutation suggests that it may be dispensable for normal eye function ([@MCS004374CRIC10]). However, multiple studies suggest that mutations in the olfactomedin domain lead to toxic intracellular protein accumulation ([@MCS004374CRIC11]; [@MCS004374CRIC18]; [@MCS004374CRIC25]). Mutations resulting in aberrant exposure of the peroxisomal targeting domain in the protein may reduce myocilin excretion ([@MCS004374CRIC7]; [@MCS004374CRIC19]). POAG-associated *MYOC* variants have also been shown to decrease myocilin solubility ([@MCS004374CRIC28]). These processes, and possibly others, produce an accumulation of intracellular myocilin aggregates, which form amyloid-like fibrils, leading to endoplasmic reticulum (ER) stress ([@MCS004374CRIC29]; [@MCS004374CRIC13]; [@MCS004374CRIC14]). This, in turn, leads to TM cell damage and dysfunction, resulting in impaired aqueous humor outflow and increased IOP ([@MCS004374CRIC1]).

Some variants in *MYOC* are well-described in association with autosomal dominant familial POAG in general, whereas other variants are specifically associated with early-onset POAG with elevated IOP. The majority of these variants are missense, with an apparent clustering in exon 3, in particular in the olfactomedin domain ([@MCS004374CRIC3]; [@MCS004374CRIC5]; [@MCS004374CRIC23]). The NM_000261.2:c.1153G\>A variant described here is also located in the olfactomedin domain, but has not been previously reported in association with POAG ([Fig. 1](#MCS004374CRIF1){ref-type="fig"}C). In silico tools predict a deleterious effect of this variant, which exchanges a highly conserved, negatively charged glutamic acid for a positively charged lysine residue in the third exon of *MYOC*.

SUMMARY {#s4}
=======

The finding of this NM_000261.2:c.1153G\>A variant provides a notable addition to our understanding of *MYOC-*associated POAG. Not only does it highlight the previously identified link between *MYOC* and POAG, but it also provides additional support for the localization of pathogenic variants to the olfactomedin domain.

Of more immediate significance, this case emphasizes the importance of encouraging and facilitating genetic testing in families with histories of eye disorders. Identification of the NM_000261.2:c.1153G\>A variant empowers this family to make more informed decisions for future generations. In particular, the proband and her siblings would be candidates to obtain early childhood genetic testing for any future children, which, if positive, may enable earlier POAG screening and intervention. Early diagnosis of *MYOC*-associated POAG may become increasingly important in the future, given current efforts to develop targeted interventions, such as TM-cell replacement from mesenchymal stem cells as well as proteostasis-based therapy to address ER stress from myocilin accumulation ([@MCS004374CRIC6]; [@MCS004374CRIC20]).

Identification of this variant also provides an opportunity to connect genetic findings with clinical outcomes, especially if the proband and her family are followed over time. Furthermore, the proband identifies as Hispanic, an ethnic group overrepresented among glaucoma patients compared to Caucasians ([@MCS004374CRIC16]). Thus, this case could inform future efforts to carry out genetic testing in Hispanic glaucoma patients, potentially identifying trends in *MYOC* variants within this population.

ADDITIONAL INFORMATION {#s5}
======================

Data Deposition and Access {#s5a}
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The *MYOC* variant described in this family was submitted to ClinVar (<https://www.ncbi.nih.nlm.gov/clinvar/>) and can be found under accession number SCV000897705. Raw data were not deposited to public access databases in the absence of patient consent but may be available through correspondence with the authors.
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